日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation

FDA批准摘要:维莫非尼用于治疗携带BRAFV600突变的埃尔德海姆-切斯特病患者

Oneal, Patricia A; Kwitkowski, Virginia; Luo, Lola; Shen, Yuan Li; Subramaniam, Sriram; Shord, Stacy; Goldberg, Kirsten B; McKee, Amy E; Kaminskas, Edvardas; Farrell, Ann; Pazdur, Richard

Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials

制定统一的患者报告结局问卷,用于评估临床试验中的骨髓纤维化症状

Gwaltney, Chad; Paty, Jean; Kwitkowski, Virginia E; Mesa, Ruben A; Dueck, Amylou C; Papadopoulos, Elektra J; Wang, Lixia; Feliciano, Joseph; Coons, Stephen Joel

U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia

美国食品药品监督管理局批准摘要:奥马西他汀甲哌琥珀酸盐用于治疗慢性粒细胞白血病

Alvandi, Firoozeh; Kwitkowski, Virginia E; Ko, Chia-Wen; Rothmann, Mark D; Ricci, Stacey; Saber, Haleh; Ghosh, Debasis; Brown, Janice; Pfeiler, Erika; Chikhale, Elsbeth; Grillo, Joseph; Bullock, Julie; Kane, Robert; Kaminskas, Edvardas; Farrell, Ann T; Pazdur, Richard

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma

FDA批准摘要:替西罗莫司用于治疗晚期肾细胞癌

Kwitkowski, Virginia E; Prowell, Tatiana M; Ibrahim, Amna; Farrell, Ann T; Justice, Robert; Mitchell, Shan Sun; Sridhara, Rajeshwari; Pazdur, Richard

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

索拉非尼与贝伐单抗联合靶向治疗可增强毒性和抗肿瘤活性

Nilofer S Azad, Edwin M Posadas, Virginia E Kwitkowski, Seth M Steinberg, Lokesh Jain, Christina M Annunziata, Lori Minasian, Gisele Sarosy, Herbert L Kotz, Ahalya Premkumar, Liang Cao, Deborah McNally, Catherine Chow, Helen X Chen, John J Wright, William D Figg, Elise C Kohn